diarrhea while on tirzepatide and Diarrhea: Managing GLP-1 Digestive Side Effects Tirzepatide Dosing - A Patient

The results were: -16,0% at 5 mg, -21,4% at 10 mg, -22,5% at 15 mg, versus -2,4% for placebo

If you're considering Mounjaro vs Zepbound, remember that Mounjaro for type 2 diabetes is not supported through telehealth due to the need for in-person monitoring and lab work

Dulaglutide shows nausea rates of approximately 8-12% at lower doses, whilst semaglutide (Wegovy) demonstrates rates around 44% in weight management trials

Jensen MD et al

Long-acting GLP-1 receptor agonists provide sustained receptor activation and clinically meaningful improvements in glycaemic control and weight in eligible patients, as recognised in NICE guidance (NG28) for type 2 diabetes management